Research Article

Functionalized Scaffold and Barrier Membrane with Anti-BMP-2 Monoclonal Antibodies for Alveolar Ridge Preservation in a Canine Model

Figure 4

(a) Representative cone bean computed tomography (CBCT) images of anti-bone morphogenetic protein 2 monoclonal antibody- (anti-BMP-2 mAb-) treated site and isotype matched control mAb-treated site. (b) Remaining bone width at 1, 2, 3, and 5 mm from the bone crest at the adjacent tooth: a statistically significant difference in remaining bone width at 2 mm and 3 mm was found between the test group () and control group () (, , respectively). (c) Bone height level at buccal aspect (mm): the amounts of buccal bone height loss in the anti-BMP-2 mAb-treated sites () and the isotype matched control mAb-treated sites () were  mm and  mm, respectively, and were statistically significantly different ().
(a)
(b)
(c)